QNRX:NASDAQ, Quoin Pharmaceuticals, Ltd.
QNRX stock overview
Quoin Pharmaceuticals, Ltd. (QNRX:NASDAQ) closed at $4.01 on October 22, 2026,
unchanged on the day.
The stock trades 82.9% below its 52-week high of $23.50
and 23.4% above its 52-week low of $3.25.
Over the past year, it lost 70.1%.
Quoin Pharmaceuticals, Ltd. is part of the Health Care sector.
Key figures
- Price
- $4.01
- Day change
- 0.00%
- Volume
- 954
- Average volume
- 544,596
- Market cap
- 19M+
- 52-week range
- $3.25 – $23.50
- 50-day average
- $5.55
- 200-day average
- $6.29
Price action over the past year
In 252 trading sessions since October 22, 2025, QNRX closed higher on 107 days (42%).
Its best day was November 11, 2025 (+41.40%) and its worst was December 5, 2025 (-36.07%).
The stock moved 10% or more in a single session 31 times.
It opened at least 5% above the previous day's high 3 times.
Recent signals
QNRX news
-
Oct 20, 2026:
Quoin Pharmaceuticals Announces Publication of Peer-Reviewed Paper on QRX003 for Netherton Syndrome in Dermatology and Therapy
-
Oct 14, 2026:
Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin Syndrome
-
Oct 6, 2026:
Quoin Pharmaceuticals Announces Acceptance of QRX003 Paper in Dermatology and Therapy
-
Sep 24, 2026:
Four Small-Cap Stocks Report New Developments (CHGA, QNRX, MYSE, LNKS)
-
Sep 22, 2026:
Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome
-
Sep 10, 2026:
Quoin Pharmaceuticals Releases New NETHERTON NOW Video: Aminah's Story Featuring Laura Wright-Sexton, MD, the Physician Who First Met Her Daughter in the ICU
-
Sep 8, 2026:
CORRECTION -- Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome
-
Sep 8, 2026:
Quoin in line for second priority review voucher if rare paediatric drug approved
About Quoin Pharmaceuticals, Ltd.
Quoin Pharmaceuticals Ltd is a pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
Similar stocks
Find more stocks like QNRX with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.